NT5E and pancreatic neoplasm: ACC comprises 1–2% of pancreatic tumors and does not carry typical genomic alterations seen in PDAC, including KRAS and TP53 mutations (205), which is suggestive that CD73 expression in PDAC may be linked to KRAS and/or TP53 mutations.